Translational Research
Structured development from biomarker selection through analytical validation, clinical feasibility and regulatory development.
CANCER DIAGNOSTIC TECHNOLOGY • RESEARCH • COMMERCIALIZATION
Earlier Cancer Diagnostics.
Intelligent Technology.
Transformative Potential.
OncoFirm™ Diagnostics is developing a connected cancer-diagnostic platform combining fluorescent lateral flow immunoassays, digital fluorescence measurement, AI-assisted signal interpretation, calibration and quality-control data, and scalable diagnostic workflows.
Multi-PlatformAssay + Reader + AI
Point-of-CarePortable diagnostic concept
Research-DrivenValidation-led development
ScalablePlatform-based architecture
COMPANY OVERVIEW
OncoFirm™
Diagnostics
OncoFirm™ Diagnostics is a biotechnology company developing next-generation cancer diagnostic technologies intended to make biomarker assessment faster, more accessible, and easier to deploy closer to the point of care.
The development strategy connects biological assays with portable electronic reading, computational interpretation, calibration information, quality-control data, manufacturing metadata, and modern healthcare data architecture.
“We are building more than an individual rapid test. We are developing a connected diagnostic platform designed for research translation, validation and future commercialization.”
Integrated Technology
Fluorescent LFA, digital measurement, AI-assisted interpretation, internal controls and metadata are designed as one ecosystem.
Commercial Scalability
A platform architecture intended to support multiple biomarker applications, future multiplex formats and scalable manufacturing.
THE STRATEGIC CASE
Six Reasons to
Watch OncoFirm
The company’s development model brings together diagnostics, engineering, data and commercialization in a unified platform rather than treating each component as an isolated product.
01
Earlier Diagnostic Access
Point-of-care formats may help move meaningful biomarker information closer to clinicians and patients when properly validated for intended use.
PortableDesigned around decentralized workflows02
Fluorescent LFA Platform
High-sensitivity fluorescent reporter concepts are being integrated with lateral flow assay engineering for cancer-associated biomarker applications.
FluorescentQuantitative signal potential03
Digital Reader Integration
Portable fluorescence measurement can reduce dependence on subjective visual interpretation and support standardized signal acquisition.
DigitalObjective electronic measurement04
AI-Assisted Interpretation
Computational methods can combine signal characteristics, controls, calibration information and test metadata to support research-stage interpretation.
AI-AssistedSignal and confidence assessment05
Platform IP Strategy
The architecture creates multiple potential intellectual-property layers across assay design, reader systems, calibration, data workflows and manufacturing methods.
Multi-LayerTechnology and process innovation06
Funding Optionality
OncoFirm’s staged research program is designed to support federal grants, research collaborations, strategic investment, licensing and co-development pathways.
FlexibleMultiple development pathwaysTECHNOLOGY & OPERATIONS
Connected Diagnostic
Architecture
01Biomarker Selection
02Assay Engineering
03Digital Reading
04AI Interpretation
Development Strategy
Biomarker Discovery & Selection → Assay Engineering → Prototype Development → Analytical Validation → Digital Integration → Clinical Feasibility → Regulatory Development → Manufacturing Scale-Up → Commercialization.
Platform Components
- Cancer-associated biomarker detection
- Fluorescent lateral flow immunoassays
- Portable electronic fluorescence reader
- Digital signal processing
- AI-assisted interpretation
- Calibration and quality-control mechanisms
Collaboration Pathways
- SBIR/STTR and federal grants
- Academic and clinical research
- Biostatistical planning
- Regulatory strategy
- Manufacturing partnerships
- Licensing and strategic investment
MARKET OPPORTUNITY
The Need for
Accessible Diagnostic
Information
Cancer diagnostic workflows often depend on centralized laboratories, sophisticated instrumentation, specialized personnel and multi-step testing processes. These requirements can limit how quickly biomarker information becomes available in decentralized settings.
OncoFirm is developing a portable, digitally interpreted diagnostic platform intended to investigate whether selected cancer-associated biomarkers can be measured in workflows closer to the point of care.
Point-of-Care
Portable formats designed around rapid workflows.
Multiplex Potential
Platform architecture intended to support multiple biomarkers.
Digital Integration
Electronic measurement and modern healthcare data connectivity.
Research Expansion
A staged pathway for additional cancer-associated biomarker applications.
FUNDING & COLLABORATION
Capital to Advance
Defined Milestones
OncoFirm welcomes discussions with qualified strategic investors, research collaborators, foundations, federal programs and industry partners interested in supporting development of next-generation cancer diagnostic technologies.
| Company | OncoFirm™ Diagnostics Corporation |
|---|---|
| Stage | Research and development / pre-commercial development |
| Focus | Cancer-associated biomarker diagnostics, fluorescent LFA, digital reader and AI-assisted interpretation |
| Funding Pathways | Grants, strategic investment, sponsored research, licensing and co-development |
| Regulatory Status | Development-stage technologies; availability and claims depend on applicable regulatory authorization |
| Investor Materials | Available to qualified parties subject to company review and applicable confidentiality requirements |
DEVELOPMENT ROADMAP
From Research
to Commercialization
Biomarker & Assay Research
Selection of candidate biomarkers, reagent systems and initial assay architecture.
Prototype & Reader Integration
Prototype fluorescent tests, electronic measurement and digital signal-processing workflows.
Analytical Validation
Performance characterization, controls, calibration and repeatability studies.
Clinical Feasibility
Appropriately designed studies to assess intended-use feasibility and refine clinical-development strategy.
Regulatory & Scale-Up
Regulatory planning, design controls, manufacturing development and commercialization preparation.
LEADERSHIP & ADVISORY NETWORK
Building a Multidisciplinary
Diagnostics Company
JB
Jonathan Adam Barash
Founder & Chief Executive Officer
Company leadership, strategic development, commercialization, partnerships and corporate growth.
CB
Cancer Biology
Scientific Advisory
Biomarker biology, oncology relevance, translational strategy and clinical research guidance.
BS
Biostatistics
Research & Study Design
Statistical planning, study endpoints, analytical performance and grant-supported research design.
RA
Regulatory & Quality
Development Advisory
Regulatory strategy, design controls, quality systems and development documentation.
Replace advisory placeholders above with named individuals only after appointments are finalized and publication is authorized.
STRATEGIC CAPITAL • RESEARCH • COLLABORATION
Interested in the future of
cancer diagnostic technology?
Request additional information about OncoFirm’s technology platform, research programs, collaboration opportunities and strategic funding initiatives.